2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1496

DNA Methylation In Six Cell and Tissue Types In Sjögren’s Syndrome Reveals Distinct Patterns Across Samples and Clustering Based On Disease Status
Abstract Number: 1717

Do Bone Marrow Edema (BME) Lesions In The Sacroiliac Joint (SIJ) Change Into Fatty Lesions Over a 3-Month Period In Patients With Axial Spondyloarthritis (axSpA)?
Abstract Number: 2094

Do Exercise Interventions For Total Hip Arthroplasty Have Therapeutic Validity? A Sensitivity Analysis Of Trials Included In a Cochrane Systematic Review
Abstract Number: 2139

Do Hyaluronic Acid Injections Delay Total Knee Replacement Surgery?
Abstract Number: 2158

Do Numbers Make a Difference?
Abstract Number: 1536

Do Patients With Ankylosing Spondylitis Have An Excess Prevalence Of Chronic Widespread PAIN?: Results From The Scotland and Ireland Registry For Ankylosing Spondylitis (SIRAS) and The Musician Study
Abstract Number: 1912

Do Persons With SLE In Poverty Rate Interactions With Providers and Health Plans Differently?
Abstract Number: 2441

Do Postural Deformities In Patients With Ankylosing Spondylitis Cause Balance Problems?
Abstract Number: 847

Do Rheumatologists (and Other Specialists) Practice What We Preach? A Study Of Serology Ordering Patterns With Attention To Subserologies When The Antinuclear Antibody By Enzyme Linked Immunosorbent Assay Is Negative; And The Clinical Significance Of These Positive Subserology Results
Abstract Number: 1306

Do Sustained Clinical Remission and Sustained Low Disease Activity Equally Predict Functional Status In Early Rheumatoid Arthritis?
Abstract Number: 1807

Do We Know How and When To Taper and Stop In Immunosuppressants In Lupus Patients?
Abstract Number: 871

Do We Need To Lower The Cut Point Of The 2010 ACR/EULAR Classification Criteria For Diagnosing Rheumatoid Arthritis?!
Abstract Number: 1372

Do We Really Identify Latent Tuberculosis? Comparison Of The Performance Of Tuberculin Skin Test and Interferon Gamma Release Assay Before Biologics: A Systematic Review and Meta-Analysis
Abstract Number: 2259

Does a Ratingen Score Of ≥ 3 At Disease Onset Define RA In ACR/EULAR 2010 Criteria Negative Patients?
Abstract Number: 1787

Does Age At Disease Onset Influence Disease Activity and Function In Rheumatoid Arthritis Patients? Results From The Ontario Best Practices Research Initiative (OBRI) Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].